Holen Sie sich die Stockscreener-App
245.47
0.50%
1.22
Vorhandelsmarkt:
245.47
Schlusskurs vom Vortag:
$244.25
Offen:
$237.63
24-Stunden-Volumen:
542.28K
Relative Volume:
1.57
Marktkapitalisierung:
$5.44B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-8.9817
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
-0.76%
1M Leistung:
+3.69%
6M Leistung:
-31.92%
1J Leistung:
-18.70%
1-Tages-Spanne:
$237.63
$251.55
1-Wochen-Bereich:
$237.63
$252.49
52-Wochen-Spanne:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
245.47 | 6.73B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Protein Chip Market Generated Opportunities, Future Scope - openPR.com
Bio Rad Laboratories Inc. Stock Analysis and ForecastExceptional growth trajectory - Autocar Professional
Single-cell Omics Market Analysis, Insights and Forecast from - openPR.com
HbA1c Testing Market Expansion Driven by Diabetes Prevalence - openPR.com
Medical Biosensors Market is projected to grow to around USD - openPR.com
Flow Cytometry in Oncology and Immunology Market Top Companies - openPR.com
What analysts say about Bio Rad Laboratories Inc. stockHigh-octane investment gains - jammulinksnews.com
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher - Yahoo Finance
Viral Vector Purification Market Top Companies StudyAgilent - openPR.com
Cancer Biomarkers Market is expected to reach USD 32.5 billion - openPR.com
Is Bio Rad Laboratories Inc. a good long term investmentFast-track wealth growth - Autocar Professional
How high can Bio Rad Laboratories Inc. stock price go in 2025Stable Stocks With High Yield - beatles.ru
Future Industry Growth Of Real-Time Polymerase Chain Reaction - openPR.com
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025 - BioSpace
Biochip Market Global Outlook Report 2025, with Focus on Microarrays and Lab-on-a-Chip - GlobeNewswire Inc.
Unexpected Trends Reshaping the Cancer Biomarkers Market - openPR.com
Laboratory Mixer Market Gains Momentum with Automation - openPR.com
Trending Report on Liquid-Based Diagnostics Market 2025-2032 - openPR.com
Bioinformatics Market Exclusive Report with Detailed Study - openPR.com
Enzyme Linked Immunosorbent Assay Market Set to Expand Through - openPR.com
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Single Cell Omics Market Size, Share, Industry Growth Report - openPR.com
Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific - Yahoo Finance
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms - Yahoo Finance
Protein Chip Market Booming as High-Throughput Proteomics - openPR.com
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout - drugdiscoverynews.com
Bio-Rad expands Droplet Digital PCR offering through strategic acquisition and platform rollout - SelectScience
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shareholders Might Be Looking For Exit - 富途牛牛
Bio-Rad's Digital PCR Play: A Strategic Move to Dominate Genomics and Diagnostics - AInvest
Bio-Rad expands digital PCR portfolio with four new platforms By Investing.com - Investing.com Nigeria
Bio-Rad Labs announces launch of four new Droplet Digital PCR platforms - BioSpectrum India
Bio-Rad expands digital PCR portfolio with four new platforms - Investing.com
Single-cell Omics Market Projected To Witness Massive Growth, - openPR.com
Trend Tracker for (BIO.B) - news.stocktradersdaily.com
RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating - MarketScreener
Bio-Rad Completes Acquisition of Stilla Technologies - TipRanks
Unpacking the Genomic Biomarkers Market's Evolution, - openPR.com
New Bioanalytical Antibodies from Bio-Rad Boost Assay Versatility - Lab Manager
Inside the Future of the RNA Extraction And Purification Market: - openPR.com
The Best Healthcare Stocks to Buy - Morningstar
Sequencing Consumables Market Deep Research with Forecast - openPR.com
Transfection Reagents and Equipment Market | Driving Gene - openPR.com
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):